Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD. Phase I in healthy volunteers and a POC trial in ulcerative colitis patients have been completed.
Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers have been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.
Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and atopic dermatitis. Phase I studies in healthy volunteers have been completed.
Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending doses. A Phase II trial in asthmatics has been completed with positive results. A Phase II clinical trial in moderate to severe COPD patients is in progress.
Novel Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of metabolic diseases. A phase II trial in Prader Willi syndrome patients is in progress.
Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015.
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.